Regeneron Pharmaceuticals (REGN) Capital Leases (2009 - 2025)

Regeneron Pharmaceuticals has reported Capital Leases for 16 years, with the latest figure at $720.0 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Leases changed 0.0% year-over-year to $720.0 million; the trailing twelve-month figure through Dec 2025 stood at $720.0 million (changed 0.0% YoY), and the FY2025 full-year result was $720.0 million, changed 0.0% from the prior year.
• Capital Leases for Q4 2025 stood at $720.0 million, roughly flat from $720.0 million in the prior quarter.
• The five-year high for Capital Leases was $720.0 million in Q1 2022, with the low at $720.0 million in Q1 2022.
• Average Capital Leases over 4 years is $720.0 million, with a median of $720.0 million recorded in 2022.
• Peak annual rise in Capital Leases reached 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
• Tracing REGN's Capital Leases over 4 years: stood at $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
• The last three Capital Leases figures came in at $720.0 million (Q4 2025), $720.0 million (Q3 2025), and $720.0 million (Q2 2025), per Business Quant data.

Peer Comparison